Stay updated on Nivolumab for High-Risk Prostate Cancer Clinical Trial

Sign up to get notified when there's something new on the Nivolumab for High-Risk Prostate Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab for High-Risk Prostate Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update or revision in the context of a Phase II clinical trial studying the effectiveness of an immune-based cancer drug, Nivolumab, for high-risk biochemically recurrent prostate cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:16:19.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of the eligibility criteria for participation in the study.
    Difference
    37%
    Check dated 2024-05-22T18:44:00.000Z thumbnail image
  8. Check
    42 days ago
    Change Detected
    Summary
    The value 'Go to the classic website' has been updated to 'Site Map' on the webpage, indicating a change in the type of intervention being discussed, possibly related to medical and healthcare publications and documentation.
    Difference
    1%
    Check dated 2024-05-01T17:38:22.000Z thumbnail image

Stay in the know with updates to Nivolumab for High-Risk Prostate Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab for High-Risk Prostate Cancer Clinical Trial page.